|
CENIX BIOSCIENCE ANNOUNCES APPOINTMENT OF
ZISI FOTEV AS NEW CHIEF BUSINESS OFFICER
 Dresden, Germany – January 27,
2004 - Cenix BioScience GmbH, the premier provider of advanced RNAi research
services, announced today that Zisi Fotev, Ph.D. has joined the company as Chief
Business Officer. In this role he will have overall responsibility for the
licensing and marketing of Cenix’ s advanced RNAi research services, negotiating
corporate partnerships and other strategic alliances.
“Zisi has more than 15 years of industry experience and an in-depth
understanding of the pharmaceutical and biotechnology arena”, said Christophe
Echeverri, Ph.D., Chief Executive Officer and Chief Scientific Officer of Cenix
BioScience. “With his outstanding track record of successful deal making, we
look forward to further strengthening Cenix’s market presence in the drug
discovery market”.
Dr. Fotev brings considerable scientific and business development experience to
Cenix, having in the past served as Vice President of Business Development at
atugen AG in Berlin and prior to that as Head of Licensing and Strategic
Alliances at Merck KGaA Pharmaceuticals division. At atugen he was instrumental
in establishing a strong market share for the target validation business and
negotiating over 15 major deals with pharmaceutical companies from the USA,
Europe and Japan.
Zisi Fotev holds a Bachelors of Science degree from the University of Western
Australia and a Ph.D. from the University of Tuebingen in Germany.
About Cenix BioScience
Cenix BioScience GmbH is a pioneering leader in genome-based high throughput
(HT) applications of RNA-mediated interference (RNAi) for the discovery and
validation of new therapeutic drug targets. Founded in 1999 as the first
biotechnology company specializing exclusively in HT-RNAi, Cenix has accumulated
unparalleled depth and breadth of experience in this field, combining high
content phenotypic analyses with proprietary genome-wide RNAi libraries for use
in key experimental systems including human cells, Drosophila and C. elegans.
Cenix is now making its unique expertise accessible to industry and academic
researchers through fully customized research service offerings. For more
information, please visit
www.cenix-bioscience.com.
|
